Skip to content
value.today

Lumos Pharma, Inc.

🇺🇸 Austin, Texas, USAPharmaceuticalsFounded 2014
Total raised
$47 M
2 rounds on record
Latest round
$34 M
Apr 2016
First round on record
Jan 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lumos Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2016$34 MNo. 2$10 to $50 million

Lumos Pharma, Inc.: Raise no. 2, Apr 2016

Investors in this round

6 investors had bought by the notice of Apr 18, 2016: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard John Hawkins · Executive Officer, Director
  • Cameron Gilbert Wheeler · Director
  • Edward Gilbert Mathers · Director
  • G. Gilbert Cloyd · Director
  • Jon S. Saxe · Director
  • Kevin S. Lelande · Director
  • Michele Gilbert Park · Director
  • Robert S. Heft · Director
  • Tracy Gilbert Saxton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “All proceeds are for working capital.”

Signed by Richard J. Hawkins, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 18, 2016. Read the notice at the SEC.

equitySEC
Jan 2014$13 MNo. 1$10 to $50 million

Lumos Pharma, Inc.: Raise no. 1, Jan 2014

Investors in this round

5 investors had bought by the notice of May 1, 2015: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard John Hawkins · Executive Officer, Director
  • Edward J. Mathers · Director
  • George Gilbert Cloyd · Director
  • Jon S. Saxe · Director
  • Kevin M. Lalande · Director
  • Robert J. Heft · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “All proceeds are for working capital.”

Signed by Richard J. Hawkins, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 1, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lumos Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2016).

    SEC Form D · Apr 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2016

That is all the official record says: Lumos Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Lumos Pharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lumos Pharma, Inc.
NameRoleNamed in
Richard John HawkinsExecutive officerApr 2016
Jon S. SaxeExecutive officerFeb 2014
Cameron Gilbert WheelerDirectorApr 2016
Edward Gilbert MathersDirectorApr 2016
G. Gilbert CloydDirectorApr 2016
Jon S. SaxeDirectorApr 2016
Kevin S. LelandeDirectorApr 2016
Michele Gilbert ParkDirectorApr 2016
Richard John HawkinsDirectorApr 2016
Robert S. HeftDirectorApr 2016
Tracy Gilbert SaxtonDirectorApr 2016
Edward J. MathersDirectorMay 2015
George Gilbert CloydDirectorMay 2015
Kevin M. LalandeDirectorMay 2015
Robert J. HeftDirectorMay 2015
Edward J MathersDirectorFeb 2014
Richard John HawkinsPromoterFeb 2014